Clinical trial Recruiting at 1 site Interventional Ages Any age to 21

Non-invasive central venous pressure monitoring in children

Official title: Non-invasive Central Venous Pressure Estimation in Pediatric Patients

Run by Compremium AG · NCT06885073 · Data updated 2026-11-12

We will test a new non-invasive ultrasound device (CPMX2) to see if it can measure central venous pressure in children who already have a central venous catheter or are undergoing cardiac catheterization.

More Central Venous Catheter trials

Quick facts

Study typeInterventional
AgesAny age to 21 Years
SexAll
Enrollment100 (estimated)
SponsorCompremium AG
Industry-sponsored
Locations1 site (Washington D.C., District of Columbia)
StatusRecruiting
StartedMarch 10, 2025
Main results expectedMarch 31, 2026
Study endsMarch 31, 2026
Registry record updatedSeptember 18, 2025
Trial IDNCT06885073 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children from birth to 21 years who already have a central venous catheter for CVP monitoring or are undergoing cardiac catheterization, weigh at least 2.5 kg, have accessible external jugular veins, and are clinically stable.

Probably not a fit

Patients unlikely to benefit include those under 2.5 kg, without a central venous catheter or inaccessible neck veins, with contraindicating neck skin lesions, active bleeding, or who are clinically unstable.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot interventional study will compare non-invasive venous occlusion pressure (VOP) readings from the CPMX2 ultrasound device with invasive central venous pressure (CVP) measurements in pediatric patients who already have a central venous catheter as part of standard care. The study will enroll patients from birth to 21 years old, with exclusions for very low weight, inaccessible neck veins, skin lesions, active bleeding, or clinical instability. Safety endpoints will document any device-related adverse events and feasibility endpoints will compare agreement between CPMX2 and invasive CVP values. The study is conducted at a single center (Children's National Hospital) and is intended to generate preliminary safety and performance data.

Why it matters

Potential benefit: If successful, the device could allow clinicians to measure CVP without placing a catheter, reducing risks like infection, thrombosis, and pneumothorax.

How similar studies have gone: Related non-invasive ultrasound and VOP methods have shown encouraging results in adults, but pediatric data are limited so this pediatric application is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* Provision of signed and dated informed consent form
* Male or female
* Age: birth to 21 years of age
* Equipped with a central venous catheter (CVC) for central venous pressure (CVP) monitoring indication as part of standard of care, or undergoing cardiac catheterization.

Exclusion Criteria:

* Weight less than 2.5kg at the time of enrollment.
* Bilateral external jugular veins not accessible due to vascular access or dressing.
* Bilateral skin lesion contraindicating neck Ultrasound
* Active bleeding
* Clinically unstable, per clinical assessment by attending physician and/or surgeon

Where it's running

  • Children's National Hospital
    Washington D.C., District of Columbia, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.